Interferon-defective tumor cells

Interferon-defective tumor cells are malignant cells characterized by a loss or impairment of the Type I interferon (IFN) signaling pathway, a critical component of the innate immune system. This defect often arises during tumor evolution as a strategy to evade immune surveillance and suppress the antiproliferative effects of IFNs. While this provides a survival advantage to the tumor, it simultaneously creates a unique vulnerability to oncolytic viruses, which require a compromised antiviral response to replicate efficiently. Therapeutic agents such as oncolytic viruses exploit this deficiency by selectively infecting and lysing these defective cells while being cleared by the intact IFN responses of healthy tissues. Molecular drivers of this phenotype include mutations or epigenetic silencing of key pathway components like JAK1, STAT1, or the IFNAR receptor. Identifying these defects through genomic or transcriptomic profiling serves as a vital biomarker for selecting patients likely to respond to virotherapy. Although not a single molecule, this cellular phenotype is the primary target for the emerging class of oncolytic biological drugs.

Other names

IFN-deficient tumor cellsInterferon-nonresponsive cancer cellsIFN-pathway deficient tumorsInterferon-resistant tumor cells

Selective viral replication and subsequent oncolysis in cells lacking functional Type I interferon signaling pathways, which normally inhibit viral protein synthesis and assembly.